Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Portfolio Pulse from
Tharimmune, Inc. presented positive clinical data for its drug TH104 at the AASLD Liver Meeting 2024. The Phase 1 trial showed TH104 was well tolerated with no unexpected adverse events, and a significant correlation between blood levels and symptom relief was observed. Phase 2 data is expected in 2025.
November 18, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune, Inc. presented promising Phase 1 data for TH104, showing good tolerability and symptom relief for chronic pruritus in liver disease. This could positively impact the stock as it progresses to Phase 2 trials.
The positive Phase 1 results for TH104, showing good tolerability and symptom relief, are likely to boost investor confidence in Tharimmune's pipeline. The anticipation of Phase 2 data in 2025 adds to the potential for future stock appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100